Gallbladder & Extrahepatic Bile Ducts
Subtle surface changes revealing malignant transformation in an ampullary adenomyoma.
Akiyama S, et al
Endoscopic detection of subtle surface changes in an ampullary adenomyoma can signal early malignant transformation, a finding with significant clinical implications for surveillance of this rare benign lesion. Ampullary adenomyomas are uncommon lesions of the ampulla of Vater that are generally con…
Source →Engineered Natural Killer Cell Derived-Extracellular Vesicles: An Acellular Immunotherapy with Cytotoxic Effects in SNU-1079 Human Cholangiocarcinoma Cells.
Gondaliya P, et al
Researchers demonstrated that extracellular vesicles (EVs) derived from NK92 natural killer cells engineered to express a truncated, signaling-deficient form of PD-1 exert potent cytotoxic activity against SNU-1079 human cholangiocarcinoma cells in both monolayer cultures and multicellular tumor sph…
Source →One-Stage Percutaneous Self-Expandable Metal Stent Placement for Malignant Biliary Obstruction: A Five-Case Series.
Izumi H, et al
A retrospective five-case series from Tokai University Hospital shows that one-stage percutaneous self-expandable metal stent (SEMS) placement achieves 100% technical success with zero procedure-related complications in patients with malignant biliary obstruction who are ineligible for standard endo…
Source →Next Generation Sequencing for the Differentiation of Benign and Malignant Biliary Strictures.
Gillmeister A, et al
A new study finds that next generation sequencing (NGS) detects malignant biliary strictures with 65% sensitivity, outperforming standard histopathology at 52% sensitivity, while maintaining comparable high specificity of 96% versus 100%. When NGS was combined with histopathology, sensitivity for ma…
Source →Long-term outcomes of preoperative chemotherapy for borderline resectable perihilar cholangiocarcinoma.
Koike S, et al
A single-centre retrospective study of 42 patients with anatomically borderline resectable perihilar cholangiocarcinoma (PHCC) found that multidisciplinary treatment incorporating preoperative gemcitabine-based chemotherapy enabled surgical resection in 81.0% of patients, with an R0 rate of 73.5% an…
Source →Long-term hormone therapy for perimenopausal and postmenopausal women.
Bofill Rodriguez M, et al
A comprehensive Cochrane systematic review of 24 randomised controlled trials involving 45,660 perimenopausal and postmenopausal women found that long-term hormone therapy (used for at least one year) carries meaningful risks alongside its benefits, with nearly 70% of the pooled data derived from tw…
Source →Serum soluble Fas levels and incidence of biliary tract cancer in a nested case-control study.
Adachi Y, et al
A prospective nested case-control study found that high serum levels of soluble Fas (sFas) are significantly associated with an increased risk of extrahepatic biliary tract cancer (eBTC), with individuals in the highest tertile of sFas showing more than three times the risk compared to those in the …
Source →Correction: The B7 family subgroup reflects tumor cell heterogeneity and patient post-operative prognosis in gallbladder cancer.
Ma C, et al
A correction has been issued for a previously published study in Biology Direct examining how B7 family immune checkpoint molecule subgroups reflect tumor cell heterogeneity and post-operative prognosis in gallbladder cancer patients. The original research investigated whether distinct B7 family exp…
Source →Is EUS-Guided Gallbladder Drainage Ready to Take Center Stage in Malignant Distal Biliary Obstruction?
Ishiwatari H
A new commentary published in Digestive Endoscopy examines whether endoscopic ultrasound (EUS)-guided gallbladder drainage is mature enough to serve as a frontline intervention for patients with malignant distal biliary obstruction, a condition most commonly caused by pancreatic cancer or cholangioc…
Source →Extended versus simple cholecystectomy for pathologic T1b gallbladder cancer: A systematic review and meta-analysis.
Cho IS, et al
Extended cholecystectomy (EC) was associated with significantly better 5-year overall survival compared to simple cholecystectomy (SC) in patients with pathologically confirmed T1b gallbladder cancer, with a hazard ratio of 0.48 (95% CI 0.33–0.70; p = 0.0001), according to a systematic review and me…
Source →Associations Between Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) and Cancer Risk: A Systematic Review and Meta-Analysis.
Lalani I, et al
A systematic review and meta-analysis of 78 observational studies found that glucagon-like peptide-1 receptor agonists (GLP-1RAs) are associated with statistically significant reductions in cancer risk for 10 of 13 obesity-associated cancers, including colorectal, endometrial, esophageal, gallbladde…
Source →Efficacy and Safety of First-Line Chemotherapy With Gemcitabine Plus Nab-Paclitaxel in Unresectable Gallbladder Cancer.
Yang Y, et al
A retrospective study of 31 patients with unresectable gallbladder cancer found that first-line chemotherapy combining nab-paclitaxel and gemcitabine (AG regimen) achieved an overall response rate of 48.4% and a disease control rate of 90.3%, with a median progression-free survival of 8.4 months and…
Source →Effectiveness and conversion outcomes of immune checkpoint inhibitors combined with lenvatinib and GEMOX chemotherapy as first-line treatment for advanced gallbladder cancer: A multicenter study.
Li S, et al
A multicenter study published in the Chinese Medical Journal evaluated the effectiveness and conversion outcomes of immune checkpoint inhibitors combined with lenvatinib and GEMOX (gemcitabine-oxaliplatin) chemotherapy as a first-line regimen for patients with advanced gallbladder cancer, a malignan…
Source →Biological determinism and the stage-dependent role of surgical approach in gallbladder cancer: A 20-year cohort study and meta-analysis.
Qiu Y, et al
A 20-year cohort study of 416 patients with gallbladder cancer (GBC) found that long-term survival is overwhelmingly dictated by tumor biology at presentation, yet achieving an R0 (complete) resection is the single most powerful modifiable protective factor, reducing the risk of death by 73% (HR 0.2…
Source →Analysis and Model Prediction of the Burden of Early-Onset Cancer Attributed to Overweight and Obesity in the Chinese Population From 1990 to 2021.
Zhang T, et al
A large-scale analysis of Chinese population data from 1990 to 2021 reveals a sustained and significant increase in the burden of early-onset cancers attributable to overweight and obesity, with age-standardized mortality rates rising at an average annual rate of 2.94% (95% CI: 2.90–2.97) in men and…
Source →